Key result
Reduced renal function is linked to ~11-fold greater BARC 3-5 bleeding during cangrelor PCI.
Why the study?
The use of cangrelor in patients with reduced renal function had never been investigated.
Is the transition from cangrelor to oral P2Y12 inhibitors safe and effective in ACS patients with reduced renal function undergoing PCI?
Observational (n=770)
Is the transition from cangrelor to oral P2Y12 inhibitors safe and effective in ACS patients with reduced renal function undergoing PCI?
Transitioning from cangrelor to oral P2Y12 inhibitors in ACS patients with reduced renal function undergoing PCI is associated with a higher rate of moderate-severe bleeding but similar ischemic outcomes compared to those with normal renal function.
Answers are grounded in this paper and cite their sources.
Requires bleeding caution during cangrelor-to-P2Y12 transition in low-eGFR PCI; leaves open dedicated prospective trials in renal impairment.
BACKGROUND: The use of cangrelor in patients with reduced renal function has never been investigated. This post-hoc analysis of the itAlian pRospective Study on CANGrELOr (ARCANGELO) study aims to assess bleeding and ischemic outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI) and transitioning from cangrelor to any oral P2Y12 inhibitors in clinical practice in subgroups stratified by renal function. METHODS: The patients were stratified according to their Estimated-Glomerular-Filtration-Rate (eGFR) value (<60[LGFR] vs ≥60[HGFR] mL/min). Bleeding Academic Research Consortium (BARC) bleedings, Major Adverse Cardiac Events (MACEs), Intraprocedural Thrombotic Events (IPTEs), and other safety parameters were assessed in the two subgroups. RESULTS: Of 770 patients included in this post-hoc analysis, 136 (17.7%) had LGFR. These patients had a higher frequency of comorbidities, including diabetes (34.6% vs. 20.0%, p = 0.0004) and atrial fibrillation (10.3% vs. 2.4%, p = 0.0001) than HGFR. A higher rate of LGFR patients had NSTEMI (54.4% vs. 44.5%) (p = 0.0350) and a multi-vessel coronary artery disease (67.6%) than HGFR ones (48.3%, p < 0.0001). While the frequencies of bleeding, IPTE, and MACEs were similarly low between LGFR and HGFR patients during the 30-day observation period, a higher proportion of LGFR patients (2.2%) experienced BARC type 3-5 (moderate-severe) bleeding compared to HGFR patients (0.2%, p = 0.0188). The type and frequency of MACEs and adverse events in this fragile population were similar to those observed in the overall patients treated with cangrelor. CONCLUSIONS: These data suggest that the transition from cangrelor to any oral P2Y12 inhibitor is a safe and effective treatment in patients with acute coronary syndrome and reduced renal function undergoing PCI in the setting of routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Capranzano et al. (2026) conducted an observational in Acute coronary syndrome (n=770). Reduced renal function (eGFR <60 mL/min) vs. eGFR ≥60 mL/min was evaluated on BARC type 3-5 (moderate-severe) bleeding (p=0.0188). In ACS patients treated with cangrelor during PCI, reduced renal function was associated with a higher rate of BARC type 3-5 bleeding compared to normal renal function.
Synapse has enriched 10 related papers. Consider them for comparative context: